By Joshua Franklin and Rebecca Spalding
NEW YORK, Feb 16 (Reuters) - Humacyte Inc, a developer of universally implantable bioengineered human tissues and organs, has agreed a deal to go public through a merger with blank-check acquisition company Alpha Healthcare Acquisition Corp , according to people familiar with the matter.
The deal would be a rare instance of a company focused on developing human tissue in laboratories coming to the public market.
The merger would give Humacyte a pre-money valuation of $800 million with the company potentially worth around $1.1 billion upon closing of the deal, the sources said.
The sources, who requested anonymity as the details are not public, said an official announcement could come as early as Wednesday.
Humacyte declined to comment.
Durham, North Carolina-based Humacyte was founded in 2004 and is developing therapeutic applications for illnesses including end-stage renal disease and repair or replacement of damaged arteries, according to its website.
Humacyte's directors include Robert Langer, a U.S. chemical engineer who is also on the board of biotechnology company Moderna Inc and is a professor at the Massachusetts Institute of Technology.
A SPAC is a shell company that raises money in an IPO to merge with a privately held company that then becomes publicly traded as a result. SPACs have emerged as a popular IPO alternative for companies, providing a path to going public with less regulatory scrutiny and more certainty over the valuation that will be attained and funds that will be raised.
Alpha Healthcare is a special purpose acquisition company (SPAC) led by investment firm Carnelian Energy Capital Management. It raised $100 million in an initial public offering $(IPO.UK)$ on the Nasdaq in September.
The SPAC is led by Rajiv Shukla, who led an earlier SPAC which merged with molecular dermatology company DermTech Inc
in 2019 and whose share price has more than doubled so far this year.
(Reporting by Joshua Franklin in Miami and Rebecca Spalding in New York; Editing by Christopher Cushing)
((joshua.franklin@thomsonreuters.com; +1 646-223-6356; Reuters Messaging: joshua.franklin.thomsonreuters.com@reuters.net))
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。